Psychedelic Therapy for PTSD: What the Evidence Says in Canada

Psychedelic therapy for post-traumatic stress disorder (PTSD) pairs a medication with structured psychotherapy. In Canada, two paths exist: MDMA-assisted therapy, which has the strongest trial evidence but is available only through individual Health Canada authorization granted case by case, and off-label ketamine, which is easier to access but has smaller, earlier evidence.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334, on 2026-05-27.

Key takeaways

• MDMA-assisted therapy has the strongest published trial evidence for PTSD. Two phase 3 trials (Mitchell 2021 and Mitchell 2023) found more participants no longer met PTSD criteria with MDMA-assisted therapy than with therapy plus placebo.
• MDMA is not approved for PTSD in Canada or the United States. In Canada, legal access requires individual Health Canada authorization, initiated by a physician on a case-by-case basis, and it is not guaranteed.
• The U.S. FDA declined to approve MDMA-assisted therapy in August 2024 and asked for more research. Canada's restricted-access pathway is governed separately.
• Off-label ketamine for PTSD has smaller and earlier evidence than MDMA, and smaller effects than ketamine shows for depression. It is more accessible in Canada because ketamine is already approved as an anaesthetic.
• Spravato (esketamine) is NOT approved for PTSD. Health Canada approved it for treatment-resistant depression only. Be cautious of any provider framing it as a PTSD treatment.
• Psychedelic therapy is not first-line for PTSD. Trauma-focused psychotherapy and certain medications are the established first treatments. No psychedelic therapy is a cure, and PTSD does not respond in everyone.

If you are living with PTSD and weighing your options, you can book a free 15-minute information call to talk through what the evidence does and does not say with our clinical team.

What is PTSD, and where does psychedelic therapy fit?

PTSD is a mental-health condition that can develop after a frightening or life-threatening event, such as combat, an assault, a serious accident, or sustained abuse. Common symptoms include intrusive memories or nightmares, avoiding reminders of the trauma, feeling on edge or easily startled, and lasting changes in mood and thinking. PTSD is treatable, and the established first treatments are trauma-focused psychotherapies (such as cognitive processing therapy, prolonged exposure, and EMDR) and certain antidepressants. Psychedelic therapy is being studied for people whose PTSD has not responded enough to these first-line treatments. It is not a replacement for them. Two approaches are relevant in Canada today: MDMA-assisted therapy, which has the most trial evidence but is investigational and tightly restricted, and off-label ketamine therapy, which is more available but supported by smaller, earlier studies. Both pair the medication with preparation and integration psychotherapy.

This article focuses on the evidence and the honest limits. For an overview of how medication-assisted care is structured, see our page on psychedelic-assisted therapy, and for how we approach this diagnosis, see what we treat: PTSD.

MDMA-assisted therapy: the most-evidenced option, still investigational

MDMA-assisted therapy is the psychedelic approach with the strongest published evidence for PTSD, and it remains investigational in Canada. In this approach, a person receives MDMA during a small number of day-long sessions, with trained therapists present, surrounded by preparation and integration sessions. The medication is meant to support the psychotherapy, not to work on its own.

Two phase 3 randomized controlled trials anchor the evidence:

• MAPP1 (Mitchell et al., 2021). In this trial of 90 adults with PTSD, 67% of those who received MDMA-assisted therapy no longer met the criteria for a PTSD diagnosis at 18 weeks, compared with 32% who received therapy plus an inactive placebo. The effect size was large (Cohen's d = 0.91) [Mitchell 2021].
• MAPP2 (Mitchell et al., 2023). This confirmatory trial of 104 adults reported that 71.2% of the MDMA-assisted therapy group no longer met PTSD criteria, compared with 47.6% in the placebo-with-therapy group, with a moderate-to-large effect size (Cohen's d = 0.7) [Mitchell 2023].

Read together, both trials found that MDMA-assisted therapy outperformed therapy with placebo. The gap between groups was larger in MAPP1 than in MAPP2, partly because more people in the MAPP2 placebo group also improved with therapy alone. That is a useful reminder that good psychotherapy helps many people on its own, and that no single number captures how any one person will respond.

An earlier phase 2 dose-response trial (Mithoefer et al., 2018) studied MDMA-assisted therapy in 26 military veterans, firefighters, and police officers, and found larger reductions in PTSD severity with active 75 mg and 125 mg doses than with a low 30 mg comparison dose [Mithoefer 2018]. This is consistent with the later phase 3 work but is smaller and earlier.

How access works in Canada, and the FDA decision

Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. They are not approved as medicines in Canada and cannot be prescribed in routine practice. Legal patient access to psilocybin- or MDMA-assisted therapy requires Health Canada authorization on a case-by-case basis, initiated by a physician on an individual patient's behalf, and it is not guaranteed. This restricted pathway has been used primarily for adults with post-traumatic stress disorder in the case of MDMA, and for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness in the case of psilocybin.

In the United States, the Food and Drug Administration (FDA) issued a Complete Response Letter in August 2024, declining to approve MDMA-assisted therapy for PTSD at that time. The FDA cited concerns including the difficulty of keeping trials properly blinded (MDMA's effects are noticeable, which can affect expectations), questions about how long benefits last, and conduct issues at some earlier trial sites. The agency asked for an additional phase 3 trial and further data. As of early 2026, that additional trial had not begun. The FDA decision applies to approval in the United States; Canada's restricted-access pathway is governed separately, and its status can change over time.

Eligibility and what to expect are assessed individually with a physician. Our team can talk you through what an application would involve on a free information call.

Off-label ketamine for PTSD: more accessible, earlier evidence

Ketamine is approved by Health Canada as an anaesthetic. Its use for PTSD, depression, and other mental-health conditions is off-label, meaning it is prescribed outside its official approval, under the oversight of provincial medical regulators. Because the medication is already legal and available, ketamine therapy is more accessible in Canada than MDMA-assisted therapy. The trade-off is that the PTSD evidence is smaller and earlier.

Two randomized controlled trials are the main references:

• Feder et al., 2014. This first proof-of-concept trial randomized 41 adults with chronic PTSD to a single intravenous ketamine infusion or to midazolam (an active comparator). Ketamine produced a rapid, significant reduction in PTSD symptoms [Feder 2014].
• Feder et al., 2021. This trial of 30 adults tested repeated ketamine infusions (six over two weeks) against midazolam for chronic PTSD. In the study, 67% of those receiving ketamine responded, compared with 20% of the midazolam group [Feder 2021].

These are small trials, and the effects ketamine shows for PTSD are generally smaller than the effects it shows for depression. Ketamine for PTSD is best understood as a clinically used, earlier-evidence option rather than a settled treatment. For the practical details, including how sessions and costs work, see what we treat: PTSD and ketamine therapy cost in Canada.

A word on Spravato (esketamine)

Spravato is a nasal spray form of esketamine. Health Canada approved it for treatment-resistant depression only. It is not approved for PTSD in Canada. If a provider presents Spravato as a PTSD treatment, treat that as a reason for caution and ask questions. Spravato may be relevant for someone whose primary diagnosis is treatment-resistant depression, but it is a separate conversation from PTSD treatment.

Comparing the two main PTSD options

The table below summarizes the key differences. It is a starting point for a conversation with a clinician, not a recommendation.

Factor	MDMA-assisted therapy	Off-label ketamine
Health Canada approval for PTSD	No (investigational; individual authorization only)	No (off-label; drug approved as an anaesthetic)
Strength of PTSD evidence	Strongest published; two phase 3 trials (Mitchell 2021, 2023)	Smaller and earlier; two RCTs (Feder 2014, 2021)
How you access it	Individual Health Canada authorization, case by case, not guaranteed	Off-label prescription under provincial regulation
Psychotherapy involved	Yes, always	Often paired with therapy; varies by program
Dosing structure	A small number of long sessions over weeks	Several shorter sessions, typically over weeks
U.S. FDA status	Declined August 2024; more research requested	Generic medication; used off-label

What treatment actually looks like

Both pathways share a three-part shape: preparation, the medication session or sessions, and integration. The structure matters as much as the medication, especially in trauma care, where pacing and a sense of safety are part of the work.

Preparation comes first. You meet your care team, build trust, learn what to expect, and set intentions. For trauma, this stage is not rushed. It is where you and your clinicians decide together whether to proceed.

The medication sessions differ between the two approaches. In the MDMA-assisted therapy trials, dosing happened during a small number of long sessions (often around eight hours), with two therapists present and continuing throughout. Ketamine sessions are usually shorter and more numerous, spread over a few weeks, with medical monitoring. In both, the room, the setting, and the people present are arranged to feel safe.

Integration follows each dosing session. This is the psychotherapy work of making sense of what came up and translating it into daily life. Many people find integration is where the lasting change happens, which is one reason psychedelic therapy is never just the medication.

Questions worth asking any provider

If you are evaluating a clinic, these questions help you tell careful, evidence-based care from marketing:

• Which medication are you proposing for my PTSD, and is it approved, off-label, or investigational in Canada?
• What does the published evidence say for my situation, and what are the honest limits?
• Who provides the psychotherapy, and how is integration handled?
• What is the screening process, and what would make me not a candidate?
• If MDMA is involved, how does the Health Canada authorization process work, and what is realistic about timing and approval?

What the evidence does not say

Being honest about the limits is part of trauma-sensitive care.

• No psychedelic therapy is a cure for PTSD. Even in the most favourable phase 3 trial, not everyone improved, and "no longer meeting PTSD criteria" is not the same as being symptom-free for life.
• MDMA-assisted therapy is not approved. Anyone pursuing it in Canada does so through the investigational, restricted-access pathway, which is authorized case by case and is not guaranteed.
• Ketamine's PTSD effects are smaller than its depression effects, and the trials are small.
• PTSD does not respond in everyone, with any current treatment. Realistic expectations matter, and they protect you.
• Psychedelic therapy is not first-line. Trauma-focused psychotherapies and certain antidepressants are the established starting points, and many people do well with them.

Safety and who may not be a candidate

Psychedelic therapy is not appropriate for everyone, and careful screening is part of responsible care. Across published trials and clinical practice, common cautions and exclusions include a personal history of psychosis (such as schizophrenia or schizoaffective disorder), which is a near-universal exclusion; bipolar disorder, which requires careful assessment because these medications can carry a risk of triggering mania; and significant cardiovascular conditions, since both MDMA and ketamine can raise heart rate and blood pressure. Current medications also matter. MDMA interacts with several antidepressants and other drugs, so a medication review is essential. Pregnancy and breastfeeding are standard exclusions, because safety data do not exist. A thorough medical and psychiatric intake is how a clinical team decides whether either pathway is reasonable for a specific person, and when it is not.

How ATMA CENA approaches PTSD

If you decide to explore your options, ATMA CENA's clinical team begins with a free 15-minute information call to orient you, followed by a comprehensive intake that reviews your trauma history, prior treatments, current medications, and medical considerations. Where ketamine is clinically appropriate, ATMA CENA's corporate clinics offer it off-label in intranasal (including Spravato and compounded), intramuscular, and oral forms; ATMA CENA does not offer intravenous ketamine. Access to MDMA-assisted therapy is not something any Canadian clinic can provide as a standard service, because it requires individual Health Canada authorization initiated by a physician, and our team can talk you through what that would involve. Care follows a preparation, medicine, and integration structure. Through our CoCare program, we can partner with your therapist if they have the appropriate training and build a service agreement with us. The information call is a clinical conversation, not a commitment.

You can book a free information call to discuss whether either pathway fits your situation.

Frequently asked questions

What is the strongest evidence for psychedelic therapy for PTSD?

The strongest published evidence is for MDMA-assisted therapy. Two phase 3 randomized controlled trials, MAPP1 (Mitchell 2021) and MAPP2 (Mitchell 2023), found that more participants no longer met PTSD criteria with MDMA-assisted therapy than with therapy plus placebo. Despite this, MDMA is not approved for PTSD in Canada or the United States.

Can I get MDMA-assisted therapy in Canada?

Only through individual Health Canada authorization. MDMA is a restricted drug, and this authorization is reviewed case by case and is not guaranteed. A physician applies on a patient's behalf. It has been used primarily for adults with PTSD, but approval depends on the individual situation.

Is ketamine effective for PTSD?

Ketamine has shown promise in two small randomized trials (Feder 2014 and Feder 2021), including a 67% response rate with repeated infusions in the 2021 study. The evidence is earlier and smaller than for MDMA, and ketamine's effects for PTSD are generally smaller than its effects for depression. It is more accessible because ketamine is already approved as an anaesthetic and can be prescribed off-label.

Does Spravato treat PTSD?

No. Spravato (esketamine) is approved by Health Canada for treatment-resistant depression only. It is not approved for PTSD. Be cautious of any provider who presents Spravato as a PTSD treatment.

How does the FDA decision affect access in Canada?

The FDA declined to approve MDMA-assisted therapy in August 2024 and asked for more research, which affects U.S. approval. Canada's restricted-access pathway operates separately. A formal Canadian approval timeline is uncertain.

Should I try other PTSD treatments first?

Generally yes. Trauma-focused psychotherapies (such as cognitive processing therapy, prolonged exposure, and EMDR) and certain antidepressants are the established first-line treatments and help many people. Psychedelic therapy is usually considered when these have not produced enough improvement.

What is the difference between MDMA-assisted therapy and ketamine for PTSD?

MDMA-assisted therapy has the strongest published trial evidence but is investigational and accessible only through individual Health Canada authorization. Ketamine has smaller, earlier evidence but is more available because it is already an approved medication used off-label. The right choice depends on your history, your goals, and a clinical assessment.

Compliance and disclaimer

This article is educational and is not medical advice. Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act and are not approved as medicines in Canada. Legal patient access to psilocybin- or MDMA-assisted therapy requires Health Canada authorization on a case-by-case basis, initiated by a physician, and it is not guaranteed. This restricted pathway has been used primarily for adults with PTSD in the case of MDMA, and for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness in the case of psilocybin. Ketamine is approved by Health Canada as an anaesthetic; use for depression, anxiety, PTSD, and other mental-health indications is off-label and is regulated by provincial medical regulators (for example, CPSA in Alberta, CPSO in Ontario, CPSM in Manitoba). Esketamine (Spravato) is approved by Health Canada for treatment-resistant depression only and is not approved for PTSD. Nothing here should be taken as a recommendation for a specific person; clinical decisions belong with a qualified prescribing physician.

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

Sources

1. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025–1033. PMID: 33972795. https://pubmed.ncbi.nlm.nih.gov/33972795/
2. Mitchell JM, Ot'alora G M, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10):2473–2480. PMID: 37709999. https://pubmed.ncbi.nlm.nih.gov/37709999/
3. Mithoefer MC, Mithoefer AT, Feduccia AA, et al. (2018). MDMA-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry, 5(6):486–497. PMID: 29728331. https://pubmed.ncbi.nlm.nih.gov/29728331/
4. Feder A, Parides MK, Murrough JW, et al. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry, 71(6):681–688. PMID: 24740528. https://pubmed.ncbi.nlm.nih.gov/24740528/
5. Feder A, Costi S, Rutter SB, et al. (2021). A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. American Journal of Psychiatry, 178(2):193–202. PMID: 33397139. https://pubmed.ncbi.nlm.nih.gov/33397139/
6. Health Canada. Guidance on requests involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
7. U.S. Food and Drug Administration. Complete Response Letter on midomafetamine (MDMA) for PTSD (August 2024). https://www.fda.gov/

Related articles

• What we treat: PTSD
• Psychedelic-assisted therapy
• Ketamine therapy cost in Canada

---

Last updated: 2026-05-27. This article is reviewed every 3 months.